Shanghai Bao Pharmaceuticals Co., Ltd has raised over USD 100 million in a Series B financing round led by Oriental Fortune Capital, with contributions from Haitong Innovation Private Fund, Sun Rock Capital, Center Lab, and YuanChuang Capital. The proceeds will fund commercialization of core drug candidates and pivotal clinical studies for new pipelines.
Company Profile
Founded in 2019, Bao Pharma specializes in recombinant human hyaluronidase-based subcutaneous drug delivery technology and assisted reproduction medical devices. Its platforms include medicinal enzyme engineering, glycoprotein drug engineering, and antibody targeting enzyme engineering centers.
Funding Details
The Series B round will support Bao Pharma’s commercialization efforts and clinical trials. The company has filed 51 patents, with 7 authorized, and established pipelines including KJ017 and SJ02, which completed pivotal studies.
Strategic Outlook
Bao Pharma aims to leverage the funding to accelerate product launches and expand its pipeline, focusing on innovative drug delivery solutions and reproductive health devices.-Fineline Info & Tech
